189 related articles for article (PubMed ID: 37111592)
1. The Novel Artemisinin Dimer Isoniazide ELI-XXIII-98-2 Induces c-MYC Inhibition, DNA Damage, and Autophagy in Leukemia Cells.
Elbadawi M; Boulos JC; Dawood M; Zhou M; Gul W; ElSohly MA; Klauck SM; Efferth T
Pharmaceutics; 2023 Mar; 15(4):. PubMed ID: 37111592
[TBL] [Abstract][Full Text] [Related]
2. Modes of Action of a Novel c-MYC Inhibiting 1,2,4-Oxadiazole Derivative in Leukemia and Breast Cancer Cells.
Zhou M; Boulos JC; Omer EA; Klauck SM; Efferth T
Molecules; 2023 Jul; 28(15):. PubMed ID: 37570631
[TBL] [Abstract][Full Text] [Related]
3. Two palladium (II) complexes derived from halogen-substituted Schiff bases and 2-picolylamine induce parthanatos-type cell death in sensitive and multi-drug resistant CCRF-CEM leukemia cells.
Zhou M; Boulos JC; Omer EA; Rudbari HA; Schirmeister T; Micale N; Efferth T
Eur J Pharmacol; 2023 Oct; 956():175980. PubMed ID: 37567459
[TBL] [Abstract][Full Text] [Related]
4. Cytotoxicity of dioncophylline A and related naphthylisoquinolines in leukemia cells, mediated by NF-κB inhibition, angiogenesis suppression, G2/M cell cycle arrest, and autophagy induction.
Yücer R; Fayez S; Feineis D; Klauck SM; Shan L; Bringmann G; Efferth T; Dawood M
Phytomedicine; 2024 Apr; 126():155267. PubMed ID: 38368795
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and cytotoxic activity of new artemisinin hybrid molecules against human leukemia cells.
Letis AS; Seo EJ; Nikolaropoulos SS; Efferth T; Giannis A; Fousteris MA
Bioorg Med Chem; 2017 Jul; 25(13):3357-3367. PubMed ID: 28456567
[TBL] [Abstract][Full Text] [Related]
6. Drug Repurposing of the Anthelmintic Niclosamide to Treat Multidrug-Resistant Leukemia.
Hamdoun S; Jung P; Efferth T
Front Pharmacol; 2017; 8():110. PubMed ID: 28344555
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of c-MYC with involvement of ERK/JNK/MAPK and AKT pathways as a novel mechanism for shikonin and its derivatives in killing leukemia cells.
Zhao Q; Assimopoulou AN; Klauck SM; Damianakos H; Chinou I; Kretschmer N; Rios JL; Papageorgiou VP; Bauer R; Efferth T
Oncotarget; 2015 Nov; 6(36):38934-51. PubMed ID: 26472107
[TBL] [Abstract][Full Text] [Related]
8. In Silico, In Vitro, and In Vivo Investigations on Adapalene as Repurposed Third Generation Retinoid against Multiple Myeloma and Leukemia.
Boulos JC; Chatterjee M; Shan L; Efferth T
Cancers (Basel); 2023 Aug; 15(16):. PubMed ID: 37627164
[TBL] [Abstract][Full Text] [Related]
9. Modulation of P-glycoprotein activity by novel synthetic curcumin derivatives in sensitive and multidrug-resistant T-cell acute lymphoblastic leukemia cell lines.
Ooko E; Alsalim T; Saeed B; Saeed MEM; Kadioglu O; Abbo HS; Titinchi SJJ; Efferth T
Toxicol Appl Pharmacol; 2016 Aug; 305():216-233. PubMed ID: 27318188
[TBL] [Abstract][Full Text] [Related]
10. Molecular mechanisms of rosmarinic acid from Salvia miltiorrhiza in acute lymphoblastic leukemia cells.
Wu CF; Hong C; Klauck SM; Lin YL; Efferth T
J Ethnopharmacol; 2015 Dec; 176():55-68. PubMed ID: 26476154
[TBL] [Abstract][Full Text] [Related]
11. Artemisinin induces selective and potent anticancer effects in drug resistant breast cancer cells by inducing cellular apoptosis and autophagy and G2/M cell cycle arrest.
Guan X; Guan Y
J BUON; 2020; 25(3):1330-1336. PubMed ID: 32862573
[TBL] [Abstract][Full Text] [Related]
12. 8,8-bis-(Dihydroconiferyl)-diferulate displayed impressive cytotoxicity towards a panel of human and animal cancer cells.
Mbaveng AT; Damen F; Guefack MF; Tankeo SB; Abdelfatah S; Bitchagno GTM; Çelik İ; Kuete V; Efferth T
Phytomedicine; 2020 Apr; 70():153215. PubMed ID: 32388040
[TBL] [Abstract][Full Text] [Related]
13. Highly potent artemisinin-derived dimers and trimers: Synthesis and evaluation of their antimalarial, antileukemia and antiviral activities.
Reiter C; Fröhlich T; Gruber L; Hutterer C; Marschall M; Voigtländer C; Friedrich O; Kappes B; Efferth T; Tsogoeva SB
Bioorg Med Chem; 2015 Sep; 23(17):5452-8. PubMed ID: 26260339
[TBL] [Abstract][Full Text] [Related]
14. Activity of drugs from traditional Chinese medicine toward sensitive and MDR1- or MRP1-overexpressing multidrug-resistant human CCRF-CEM leukemia cells.
Efferth T; Davey M; Olbrich A; Rücker G; Gebhart E; Davey R
Blood Cells Mol Dis; 2002; 28(2):160-8. PubMed ID: 12064912
[TBL] [Abstract][Full Text] [Related]
15. Isopetasin and S-isopetasin as novel P-glycoprotein inhibitors against multidrug-resistant cancer cells.
Abdelfatah S; Böckers M; Asensio M; Kadioglu O; Klinger A; Fleischer E; Efferth T
Phytomedicine; 2021 Jun; 86():153196. PubMed ID: 32229058
[TBL] [Abstract][Full Text] [Related]
16. Cytotoxicity of ungeremine towards multi-factorial drug resistant cancer cells and induction of apoptosis, ferroptosis, necroptosis and autophagy.
Mbaveng AT; Bitchagno GTM; Kuete V; Tane P; Efferth T
Phytomedicine; 2019 Jul; 60():152832. PubMed ID: 31031043
[TBL] [Abstract][Full Text] [Related]
17. Jozimine A
Damiescu R; Yücer R; Klauck SM; Bringmann G; Efferth T; Dawood M
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542061
[TBL] [Abstract][Full Text] [Related]
18. Bcl-2, bax and bcl-xL expression in human sensitive and resistant leukemia cell lines.
Nuessler V; Stötzer O; Gullis E; Pelka-Fleischer R; Pogrebniak A; Gieseler F; Wilmanns W
Leukemia; 1999 Nov; 13(11):1864-72. PubMed ID: 10557064
[TBL] [Abstract][Full Text] [Related]
19. Genomic and transcriptomic profiling of resistant CEM/ADR-5000 and sensitive CCRF-CEM leukaemia cells for unravelling the full complexity of multi-factorial multidrug resistance.
Kadioglu O; Cao J; Kosyakova N; Mrasek K; Liehr T; Efferth T
Sci Rep; 2016 Nov; 6():36754. PubMed ID: 27824156
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of cell migration and induction of apoptosis by a novel class II histone deacetylase inhibitor, MCC2344.
Dawood M; Fleischer E; Klinger A; Bringmann G; Shan L; Efferth T
Pharmacol Res; 2020 Oct; 160():105076. PubMed ID: 32659428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
